) revealed that physicians across the U.S. have implanted more
than 15,000 Impella pumps in patients needing hemodynamic
support. Mercy General Hospital in Sacramento, CA is the place
where the 15,000th Impella procedure took place with an Impella
pump that provided prophylactic circulatory support.
ABIOMED INC (ABMD): Free Stock Analysis
CYBERONICS INC (CYBX): Free Stock Analysis
IDEXX LABS INC (IDXX): Free Stock Analysis
THORATEC CORP (THOR): Free Stock Analysis
To read this article on Zacks.com click here.
Currently, Impella 2.5 is the Smallest Heart Pump in the world.
It is a widely used and studied percutaneous circulatory support
Abiomed also revealed that its higher flow Impella CP device has
also been implanted in more than 1,000 patients globally. The
device got the 510(k) clearance from the Food & Drug
Administration (FDA) in Sep last year. The 1,000th Impella CP
procedure took place at the Ochsner Medical Center in New
The Impella CP is very useful in treating patients who need
percutaneously deployed hemodynamic support device. It is a vital
device in the cardiology toolbox that can be used at ease.
ABMD is also in the process of developing Impella pediatric
device. The device will be helpful in treating infants and
children with heart failure. However, the device has not yet
received clearance from the FDA.
Abiomed is a leading provider of heart support technologies. Its
Impella platform consists of minimally invasive products with
flow levels that vary with device size depending on the patient's
need for hemodynamic support.
About 775 hospitals in the U.S. have acquired Impella products,
with over 2,000 implanting physicians. Moreover, 66 new hospitals
adopted the latest Impella CP, with 172 customer sites in the
Abiomed, a Zacks Rank #3 (Hold) stock, reported fiscal
2013-first-quarter earnings per share of 5 cents (excluding legal
expenses and the medical device excise tax) that missed the Zacks
Consensus Estimate by a penny. The quarterly EPS was lower than
the year-ago earnings of 8 cents.
Revenues in the quarter grew 10% year over year to $42.7 million,
in line with the Zacks Consensus Estimate. This marked the 15th
straight quarter in which Abiomed recorded year-over-year
double-digit growth. The improvement was led by solid sales of
the Impella heart pumps and patient utilization of the Impella
device in the quarter.
Globally, Impella revenues rose 12% to $38.7 million in the
quarter. U.S. Impella revenues grew 7% to $35.4 million. ABMD
opened 27 new U.S. sites for Impella 2.5 in the quarter.
ABMD reiterated it revenue guidance for fiscal 2014. Management
forecasts revenues to grow 14%-17% to $180-$185 million for the
year. Global Impella sales are expected to increase by 20%.
Currently, other medical stocks that are performing well include
), both with a Zacks Rank #1 (Strong Buy), and
IDEXX Laboratories, Inc.
) with a Zacks Rank #2 (Buy).